Wednesday, 26 August 2026European Markets

CRESCENT Stock Over 17% Up In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of CRESCENT (BEL 20: OPTI.BR) rose by a staggering 17.65% in 5 sessions from €0.02 to €0.02 at 05:12 EST on Wednesday, after five successive sessions in a row of losses. BEL 20 is jumping 0.46% to €3,558.79, following the last session's upward trend.

About CRESCENT

Crescent NV provides IoT integration services in Belgium. The company offers IoT engineering network services. It also produces and develops energy-efficient lighting technology. In addition, the company is involved in cloud and infrastructure services. Crescent NV was founded in 2018 and is based in Leuven, Belgium.

Earnings Per Share

As for profitability, CRESCENT has a trailing twelve months EPS of €-0.004.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CRESCENT's stock is considered to be overbought (>=80).

Volatility

CRESCENT's last week, last month's, and last quarter's current intraday variation average was a negative 3.07%, a negative 1.72%, and a positive 1.84%.

CRESCENT's highest amplitude of average volatility was 3.07% (last week), 2.08% (last month), and 1.84% (last quarter).

Volume

Today's last reported volume for CRESCENT is 633143 which is 94.33% below its average volume of 2003310.

More news about CRESCENT (OPTI.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com